**GABA\(_B\) receptor signaling in the caudate putamen is involved in binge-like consumption during a high fat diet in mice**

Runan Sun\(^1\), Taku Tsunekawa\(^1,2\*\), Tomonori Hirose\(^3\), Hiroshi Yaginuma\(^4\), Keigo Taki\(^4\), Akira Mizoguchi\(^1,2\), Takashi Miyata\(^4\), Tomoko Kobayashi\(^5\), Mariko Sugiyama\(^6\), Takeshi Onoue\(^7\), Hiroshi Takagi\(^8\), Daisuke Hagiwara\(^9\), Yoshihiro Ito\(^1\), Shintaro Iwama\(^1\), Hidetaka Suga\(^3\), Ryoichi Banno\(^1,3\) & Hiroshi Arima\(^1,2\*\)

Previous studies suggest that signaling by the \(\text{GABA}\text{B}\) receptor (GABA\(_B\)R) is involved in the regulation of binge eating, a disorder which might contribute to the development of obesity. Here, we show that intermittent access to a high fat diet (HFD) induced binge-like eating behavior with activation of dopamine receptor d1 (drd1)-expressing neurons in the caudate putamen (CPu) and nucleus accumbens (NAc) in wild-type (WT) mice. The activation of drd1-expressing neurons during binge-like eating was substantially increased in the CPu, but not in the NAc, in corticostriatal neuron-specific GABA\(_B\)R-deficient knockout (KO) mice compared to WT mice.

Treatment with the GABA\(_B\)R agonist, baclofen, suppressed binge-like eating behavior in WT mice, but not in KO mice, as reported previously. Baclofen also suppressed the activation of drd1-expressing neurons in the CPu, but not in the NAc, during binge-like eating in WT mice. Thus, our data suggest that GABA\(_B\)R signaling in CPu neurons expressing drd1 suppresses binge-like consumption during a HFD in mice.

Obesity, which has recently become a global epidemic, is caused when energy intake overwhelms energy expenditure. Predisposing factors for obesity include excess intake of palatable and calorie-rich food, such as a high-fat diet (HFD), as well as irregular eating, such as a binge-eating disorder\(^1\). Binge eating is characterized by the consumption of large amounts of food in a short duration, with a loss of control from overeating\(^2\). Given that the prevalence of binge eating is increasing\(^2\), a need exists to clarify the mechanisms causing such complex feeding behavior\(^3\).

Feeding is controlled by both homeostatic and reward systems\(^4\). The latter is mainly composed of the mesolimbic system, in which dopaminergic neurons in the ventral tegmental area (VTA) project to the nucleus accumbens (NAc) and prefrontal cortex (PFC), while dopaminergic neurons in the substantia nigra pars compacta (SNc) mainly project to the caudate putamen (CPu) in the striatum\(^5,6\). Recent studies have shown that dysfunction of dopaminergic neurons in the mesolimbic system is associated with the onset of obesity and eating disorders\(^7\).

Intermittent access to a HFD reportedly causes binge-like eating behavior in a rodent model, as shown by increases in the motivation to consume\(^8\) and gradual increases in consumption\(^9,10\). These behaviors are accompanied by the activation of neurons in the VTA as well as striatum, where an increase in extracellular dopamine concentration has been shown in a rodent model\(^11\). Thus, intermittent access to a HFD is a good model to clarify mechanisms underlying the binge eating of such a diet.

Gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, acts on two types of receptors: ionotropic GABA\(_A\) and GABA\(_C\); and metabotropic GABA\(_B\) receptors (GABA\(_B\)Rs) that are located both pre- and postsynaptically\(^12,13\). We previously reported that the GABA\(_B\)R agonist, baclofen, reduced food intake as well as body weight (BW) in obese mice\(^14\), and BW in obese patients\(^15\). Baclofen is also effective in reducing binge-like...
Intermittent access to a HFD induces binge-like eating with neural activation in the striatum. (A and B) The mRNA expression levels of cFos (A) and ΔFosB (B) in the caudate putamen (CPu) in binge and control mice groups. (C and D) The phosphorylation of dopamine- and cyclic-AMP–regulated phosphoprotein of molecular weight 32,000 (DARPP32) in the CPu in binge (C) and control (D) groups. (E and F) The mRNA expression levels of cFos (E) and ΔFosB (F) in the nucleus accumbens (NAc) in binge and control groups. (G and H) The phosphorylation of DARPP32 in the NAc in binge (G) and control (H) groups. All values are mean ± SEM. Statistical analyses were performed using two-way factorial analysis of variance (ANOVA) (A, B, E, and F) followed by Sidak’s post-hoc test or an unpaired t-test (C, D, G, and H). *p < 0.05 versus 0 min in the same group. **p < 0.05 versus control. See also Supplemental Table 2 for details on statistics.

eating in rodents as well as binge eating in humans. Our recent study has shown that GABABR signaling in the mesolimbic system is involved in the suppression of the binge-like consumption of a HFD in mice, although the precise sites of action in the system still remain unclear.

In the present study, we employed corticostriatal neuron-specific GABABR-deficient mice, and subjected them to intermittent access to a HFD in order to clarify critical sites of GABABR signaling in the suppression of binge-like consumption with a HFD.

Results
Intermittent access to a HFD induces binge-like eating with neural activations in the striatum. The experimental protocol used is described in Supplemental Fig. 1A. As shown in Supplemental Fig. 1B, BW on the experimental day did not differ between control and binge groups. On the experimental day, mice in the binge group only consumed a HFD over 2 h, with consumed calories higher than in the control group (Supplemental Fig. 1C). We evaluated cFos expression at 30 and 120 min in the limbic system in a binge-like eating model based on previous studies. The mRNA expression level of cFos in the CPu was significantly increased 30 and 120 min after the consumption of a HFD compared to values at time 0 in the binge group (Fig. 1A). While the cFos mRNA expression level in the CPu was increased at 30 min in the control group, absolute values were lower in the control group compared to the binge group (Fig. 1A). The cFos mRNA expression levels in the CPu were proportional to HFD consumption at 30 min in the binge group (Supplemental Fig. 1D). The mRNA expression level of ΔFosB in the CPu was increased significantly 120 min after the consumption of a HFD in the binge, but not control group (Fig. 1B). The phosphorylation of dopamine- and cyclic-AMP–regulated phosphoprotein of molecular weight 32,000 (DARPP32), a prominent mediator of dopamine signaling in the striatum, in the CPu was significantly increased at 30 min in the binge group (Fig. 1C), but not in the control group (Fig. 1D). The mRNA expression levels of both cFos and ΔFosB in the NAc were significantly increased by the consumption of a HFD at 30 and 120 min in the binge, but not control group (Fig. 1E and F). The phosphorylation of DARPP32 was also significantly increased at 30 min in the binge (Fig. 1G), but not control group (Fig. 1H). The cFos mRNA expression levels in the PFC were significantly increased at 30 min compared to values at 0 min in both binge and control groups (Supplemental Fig. 1E). The ΔFosB mRNA expression levels in the PFC were significantly increased at 120 min compared to values at 0 min in both binge and control groups.

Figure 1. Intermittent access to a HFD induces binge-like eating with neural activation in the striatum. (A and B) The mRNA expression levels of cFos (A) and ΔFosB (B) in the caudate putamen (CPu) in binge and control mice groups. (C and D) The phosphorylation of dopamine- and cyclic-AMP–regulated phosphoprotein of molecular weight 32,000 (DARPP32) in the CPu in binge (C) and control (D) groups. (E and F) The mRNA expression levels of cFos (E) and ΔFosB (F) in the nucleus accumbens (NAc) in binge and control groups. (G and H) The phosphorylation of DARPP32 in the NAc in binge (G) and control (H) groups. All values are mean ± SEM. Statistical analyses were performed using two-way factorial analysis of variance (ANOVA) (A, B, E, and F) followed by Sidak’s post-hoc test or an unpaired t-test (C, D, G, and H). *p < 0.05 versus 0 min in the same group. **p < 0.05 versus control. See also Supplemental Table 2 for details on statistics.
As reported previously, the mRNA expression levels of cFos and ΔFosB in the CA1 region of the hippocampus were significantly higher in male knockout (KO) mice compared to wild-type (WT) mice (Supplemental Fig. 1A and B). In contrast, no significant differences were observed in the number of DA1-positive cells in male KO mice compared to WT mice (Supplemental Fig. 1A and B).

Immunohistochemistry in the striatum showed that while cFos-positive cells in DA1-positive neurons were not significantly different between genotypes at all measurement times, there were significant differences in the number of cFos-positive cells in DA1-negative neurons (cFos+/DA1−) in the CPu and NAc between genotypes 30 min after the consumption of a HFD (Supplemental Fig. 1C and D). Significant differences in the number of cFos-positive cells in DA1-negative neurons (cFos+/DA1−) in the CPu and NAc were not found between genotypes (Supplemental Fig. 1E and F).

Baclofen suppresses binge-like eating and neural activation in the CPu. As reported previously, treatment with baclofen, a GABA_6 receptor agonist, significantly reduced HFD consumption compared to vehicle in WT mice, but not in KO mice (Supplemental Fig. 4A). Baclofen suppressed elevation of cFos and ΔFosB mRNA expression levels in the CPu compared to vehicle at 30 and 120 min after the consumption of a HFD (Fig. 4A and B). The phosphorylation of DARPP32 was also significantly suppressed by baclofen compared to vehicle (Fig. 4C). In contrast, baclofen did not affect the mRNA expression levels of cFos or ΔFosB, or the phosphorylation of DARPP32 in the NAc, after the consumption of a HFD (Fig. 4D–F).
Suppressive effects of baclofen on activation of drd1-expressing neurons in the CPu were absent in KO mice. The suppressive effects of baclofen on cFos and ΔFosB mRNA expression levels, as well as the phosphorylation of DARPP32 in the CPu, were absent in KO mice in the binge group (Fig. 5A–C). Baclofen also did not affect the mRNA expression levels of cFos and ΔFosB, and the phosphorylation of DARPP32 in the NAc in both WT and KO mice (Fig. 5D–F).

Immunohistochemical staining in the striatum showed that baclofen significantly reduced the number of cFos-positive cells in drd1-positive neurons (cFos+/drd1+) in the CPu 30 min after the consumption of a HFD in WT, but not in KO mice (Fig. 6A and B). Significant differences were not found in the number of cFos-positive cells in drd1-positive neurons (cFos+/drd1+) in the NAc between vehicle and baclofen groups in both WT and KO mice (Fig. 6C and D). Also, no significant differences were evident in the numbers of cFos-positive cells in

Figure 3. GABAA-R deficiency in striatum neurons increases expression of cFos+/drd1+ cells in CPu neurons. (A and C) Representative photographs showing the staining of cFos (green), dopamine receptor d1 (drd1) (red), and DAPI (blue) in the caudate putamen (CPu) (A) and nucleus accumbens (NAc) (C) of wild-type (WT) and knockout (KO) mice in the binge group. White arrowheads show the colocalization of cFos and drd1. Scale bars: 50 μm. (B and D) cFos-positive cells in drd1-positive neurons (cFos+/drd1+) in the CPu (B) and NAc (D) of WT and KO mice in the binge group. All values are mean ± SEM. Statistical analyses were performed using two-way factorial analysis of variance (ANOVA) followed by Sidak’s post-hoc test (B and D). ns: not significant. #p<0.05 versus 0 min in WT mice. †p<0.05 versus 0 min in KO mice. *p<0.05 versus WT mice. See also Supplemental Table 2 for details on statistics.
drd1-negative neurons (cFos+/drd1−) in the CPu and NAc between vehicle and baclofen groups in both WT and KO mice (Supplemental Fig. 5A and B).

**Discussion**

In the present study, we showed that drd1-expressing neurons in the CPu and NAc were significantly activated in WT mice after binge-like consumption on a HFD. Our data also showed that activation of drd1-expressing neurons was significantly enhanced in the CPu, but not in the NAc, in corticostriatal neuron-specific GABA\(_A\)R-deficient mice compared to WT mice after binge-like consumption on a HFD. Furthermore, the GABA\(_A\)R agonist, baclofen, suppressed the activation of neurons expressing drd1 in the CPu and decreased binge-like eating by WT mice on a HFD, but not that of KO mice. These data suggest GABA\(_A\)R signaling in the CPu is crucial for the suppression of binge-like eating while on a HFD.

Previous studies using binge-like eating models in rats showed that the number of c-Fos–positive cells in the CPu, as well as \(\Delta\)FosB expression and DARPP32 phosphorylation in the NAc, were increased after the intake of palatable food\(^{25,26}\). These data are consistent with the findings in the current study that neurons in the CPu and NAc were activated in WT mice with intermittent access to a HFD. Previous studies also showed that the dorsal medial PFC is associated with binge-like eating\(^{24}\), whereas the ventral medial PFC is associated with resistance.
to binge-like eating\textsuperscript{27}. While our data did not reveal any difference in dopamine receptor signaling in the PFC between binge and control groups, our analyses of whole PFC do not exclude the role of PFC in binge-like eating.

We previously reported that GABAB\textsubscript{R} signaling in the mesolimbic system is involved in the suppression of binge-like consumption under a HFD\textsuperscript{22}; this was confirmed in the current study showing that binge-like eating during a HFD was enhanced in corticostriatal neuron-specific GABAB\textsubscript{R}-deficient mice. In addition, we clearly demonstrated that the suppression of binge-like eating during a HFD by baclofen was accompanied by decreased activity of drd1-expressing neurons in the CPu, but not in the NAc. The site of activation in the striatum, reportedly, depended on the type of food or drink ingested: ethanol (EtOH) infusion, but not fat intake, significantly increased NAc dopamine signaling, while fat intake, but not EtOH infusion, significantly increased CPu dopamine signaling\textsuperscript{28}. It was also shown that taste quality regulated dopamine release in the NAc, while dopamine in the CPu was released when a nutritive solution, but not a non-nutritive solution, was ingested\textsuperscript{29}. Taken together with our findings, it is suggested that the CPu plays an important role in regulating the binge-like consumption of calorie-enrich palatable food such as when on a HFD, where GABAB\textsubscript{R} signaling suppresses the activity of drd1-expressing neurons.

Our data showed that the consumption of a HFD did not affect drd1 expression levels in the CPu, and that these levels did not differ between WT and KO mice. Taken together with the findings that a GABAB\textsubscript{R} agonist suppressed mRNA expression levels of cFos and ΔFosB as well as the phosphorylation of DARPP32 in the CPu of wild-type (WT) and knockout (KO) mice of a binge group treated with vehicle and baclofen, it is suggested that GABAB\textsubscript{R} signaling suppresses the activity of drd1-expressing neurons.

Our data showed that the consumption of a HFD did not affect drd1 expression levels in the CPu, and these levels did not differ between WT and KO mice. Taken together with the findings that a GABAB\textsubscript{R} agonist suppressed mRNA expression levels of cFos and ΔFosB as well as the phosphorylation of DARPP32 in the CPu of wild-type (WT) and knockout (KO) mice of a binge group treated with vehicle and baclofen, it is suggested that GABAB\textsubscript{R} signaling suppresses the activity of drd1-expressing neurons.

The first limitation in the present study is that we cannot rule out the possibility that GABAB\textsubscript{R} signaling in the medial PFC and orbitofrontal cortex (OFC), which are important sites for decision making and related to reward-based behavior\textsuperscript{30,31}, might be affected in KO mice, since GPR88-positive neurons include not only striatal neurons but also those in the medial PFC and OFC\textsuperscript{32}. Second, we did not measure concentrations of dopamine in the striatum but used surrogate markers for dopamine signaling. Third, the systemic injection of baclofen

---

**Figure 5.** Suppressive effects of baclofen on cFos and ΔFosB mRNA expression levels as well as phosphorylation of DARPP32 in the CPu were absent in KO mice. (A–C) The mRNA expression levels of cFos (A) and ΔFosB (B), and phosphorylation of dopamine- and cyclic-AMP–regulated phosphoprotein of molecular weight 32,000 (DARPP32) protein (C) in the caudate putamen (CPu) in wild-type (WT) and knockout (KO) mice of a binge group on a high fat diet (HFD) treated with vehicle and baclofen. (D–F) The mRNA expression levels of cFos (D) and ΔFosB (E), and phosphorylation of DARPP32 (F) in the nucleus accumbens (NAc) in WT and KO mice of a binge group treated with baclofen and vehicle. All values are mean ± SEM. Statistical analyses were performed using two-way factorial analysis of variance (ANOVA) followed by Sidak’s post-hoc test (A–F). ns: not significant, veh: vehicle, bac: baclofen. *p < 0.05 versus vehicle in WT mice. See also Supplemental Table 2 for details on statistics.
was employed in the current study. To clarify the site of action, a local infusion of baclofen would be warranted in future studies. Fourth, while our study focused on dopamine receptor d1 signaling, this does not exclude the possibility that dopamine receptor d2 signaling in the CPu and NAc might also be involved in binge-like consumption that occurs during a HFD.

In conclusion, our data suggest that GABABR signaling in CPu neurons expressing drd1 suppresses binge-like consumption during a HFD in mice.

**Methods**

**Mice.** All experiments were performed using 9-week-old male mice. All animal procedures were approved by the Animal Care and Use Committee of Nagoya University Graduate School of Medicine and performed in accordance with National Institutes of Health animal care guidelines. The study was carried out in compliance...
with ARRIVE guidelines. Mice were maintained on a 12 h light/12 h dark cycle (lights on from 09:00 to 21:00) in a temperature-controlled barrier facility, with free access to water and food. Age-matched littermates were used for all experiments.

**Mice with GPR88-sepecific deletion of GABA<sub>B</sub> receptor.** We crossed GABA<sub>B</sub>R<sup>lox511/lox511</sup> mice with GPR88-Cre heterozygous mice to generate GABA<sub>B</sub>R<sup>lox511/lox511</sup> GPR88-Cre mice (KO mice), GABA<sub>B</sub>+/lox511 GPR88-Cre mice, and GABA<sub>B</sub>R<sup>lox511/lox511</sup> littermate controls (WT mice). GABA<sub>B</sub>R<sup>lox511/lox511</sup> mice have been generated previously<sup>32</sup>. GPR88-Cre transgene (RRID: IMSR_RBRC10287) mice express functional Cre-recombinase mainly in medium spiny neurons and a small population of parvalbumin-positive interneurons in the CPu and NAc<sup>32</sup>. GPR88-Cre transgene mice were provided by RIKEN BRC (Koyodai, Japan) through the National Bio-Resource Project of the Ministry of Education, Culture, Sports, Science and Technology, Japan. DNA was extracted from the tail of each experimental mouse at the age of 10 days. DNA was subjected to genotyping analyses by PCR with KOD FX DNA polymerase (Toyobo, Osaka, Japan) and oligonucleotide primers. The PCR was performed with a SimpliAmp™ Thermal Cycler (Applied Biosystems™, Foster City, CA, USA). The conditions were 5 min at 95 °C followed by 30 cycles at 95 °C for 30 s, 56 °C for 20 s, and 72 °C for 60 s with a 7 min final extension. Primer sequences used for genotyping of GABA<sub>B</sub>R<sup>lox511/lox511</sup> and GPR88-Cre mice were as follows:

- **GABA<sub>B</sub>R** forward, 5'-TGG GGT GTG TCC TAC ATG CAG CGG ACGG; reverse, 5'-GCT CTT CAC CTT TCA ACC CAG CCT ACAG GC AGGC;
- **GPR88-Cre** forward, 5'- ACC TGA TGG ACA TGT TCA GGG ATCG; reverse, 5'-TCC GGT TAT TCA ACT TGC ACC ATG C.

All GABA<sub>B</sub>R<sup>lox511/lox511</sup> mice and GPR88-Cre mice were backcrossed more than 10 generations onto a C57BL/6 J background.

**Training and assessment of binge-like eating behavior.** We used a published protocol<sup>22</sup> to train and assess binge-like eating behavior in male mice (Supplemental Fig. 1A). After acclimation, WT mice (9 weeks of age) were exposed to both a chow diet (CD; CE-2, CLEA Japan, Tokyo, Japan; 24.9% protein, 4.6% fat, and 70.5% carbohydrate) and a HFD (Test Diet 58Y1; PMI Nutrition International, KS, USA; 18.3% protein, 60.9% fat, and 20.1% carbohydrate) for 2 days, and then exposed to only CD for 5 days. Next, the mice were divided into two groups: “Binge group” and “Control group”, on the experimental day. The mice in the binge group were given free access to HFD and CD for 120 min (zeitgeber time [ZT] 12 to 14: 21:00 to 23:00), while the mice in the control group were continuously fed only CD. Then HFD and CD intakes were measured for 120 min (ZT 12 to 14).

The food intake of mice on both the CD and HFD were assessed by multifeeders (Shinfactory, Fukuoka, Japan). Mice in the binge group were sacrificed at 30 and 120 min after the start of access to HFD and CD (i.e., 21:30 and 23:00, respectively) and those in the control group were also sacrificed at 21:30 and 23:00. The GABA<sub>B</sub>R agonist, baclofen (Sigma–Aldrich, St Louis, MO, USA), dissolved in 0.9% saline, or vehicle (saline) were administered intraperitoneally 30 min before the beginning of the dark cycle (ZT 12) on the experimental day. The dose of baclofen was 3 μg/10 μL/g body weight.

**Extraction of brain tissues.** After mice were sacrificed, the CPu, NAc, and PFC were rapidly dissected from 2-mm thick coronal sections of fresh brain using an Alto Stainless Steel Coronal 1.0 mm Brain Matrix (Roboz Surgical Instrument Co., MD, USA) and Sharp Matrix Blades (Kent Scientific Co., Torrington, CT, USA). The NAc was punched out using 1.5-mm MilTex Disposable Biopsy Punches (Integra Life Science, West Valley City, NJ, USA) with the anterior commissure in the center of the circle. The CPu and PFC were dissected using tweezers (MA-65, Natsume Seisakusho Co., Tokyo, Japan) <sup>33</sup>. The dissected tissues were immediately frozen in liquid nitrogen until RNA extraction.
Determination of mRNA levels by qRT–PCR. Total RNA was extracted from samples using TRIzol (Invitrogen, Carlsbad, CA, USA) and an RNAeasy kit (QIAGEN, Hilden, Germany). Copy DNA was synthesized from 60 to 150 ng total RNA using a ReverTra Ace qPCR RT Kit (TOYOBO, Osaka, Japan). Quantitative reverse transcriptase (qRT)–PCR reactions were carried out using Brilliant III Ultra-Fast SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA, USA), and samples were processed using a CFX Connect Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The relative mRNA levels of cfos and ΔFosB were assessed by qRT-PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. The qRT–PCR reactions were carried out, and relative mRNA expression levels were calculated using a comparative Ct method as described previously.34,35 The sequences of primers are described in Supplemental Table 1.

Determination of protein levels by western blot. Samples of CPu or NAc were lysed in a buffer (100 μL) containing Tris (10 mM, pH 7.4), NaF (50 mM), NaCl (150 mM), SDS (0.1%), Na3VO4 (2 mM), EDTA (5 mM), Triton X-100 (1%, Sigma–Aldrich) sodium deoxycholate (minimum 1%), and a protease inhibitor mix (1%; Roche, Stockholm, Sweden). After centrifuging samples, protein concentrations in the supernatants were determined using a bicinchoninic acid kit (Sigma–Aldrich). Protein (7.5–10 μg per sample) samples were run on a Bis–Tris gel (10%; Invitrogen) and transferred onto polyvinylidine fluoride membranes (Millipore, Burlington, MA, USA). Blots were blocked for 1 h in Blocking One, Blocking One P (Nacalai Tesque Inc., Kyoto, Japan) or in TBS-T solution [10 mM Tris–HCl (pH 7.4), 150 mM NaCl, and 0.1% Tween] containing 5% skim milk. Membranes were incubated overnight at 4 °C with the following antibodies: rabbit anti-DARPP32 phosphorylated at Thr34 (#12,438; Cell Signaling Technology, Danvers, MA, USA, RRID: AB_2797914) and mouse anti-dopamine D1R/Drd1 (clone SG2-D1; #NB110-60,017; Novus Biologicals, Briarwood Avenue, USA, RRID: AB_905382). Primary antibodies were probed with horse radish peroxidase–conjugated donkey anti-rabbit IgG (NA934; GE Healthcare, Little Chalfont, UK, RRID: AB_772206) and horse radish peroxidase–conjugated sheep anti-mouse IgG (NA931; GE Healthcare, Little Chalfont, UK, RRID: AB_772210) for 1 h at room temperature. To improve sensitivity and the signal-to-noise ratio, Can Get Signal Immunoreaction Enhancer Solution (TOYOBO, Osaka, Japan) was used for the dilution of primary and secondary antibodies. Immunoreactivity was detected using ECL Prime Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA). The membranes were stripped and incubated with rabbit antibodies against nonphosphorylated DARPP32 antibody (ab40801; Abcam, Cambridge, UK, RRID: AB_731843) and rabbit anti-beta actin antibody (ab22877; Abcam, Cambridge, UK, RRID: AB_2305186) for normalization. Full immunoblots are displayed in Supplemental Fig. 6.

Brain collection for immunohistochemistry. Male mice were deeply anesthetized using 2.0% isoflurane with an animal anesthetizer device (MK-AT210; Muromachi Kikai, Tokyo, Japan) and transcardially perfused with a cold fixative containing paraformaldehyde (4%; PFA) in phosphate buffered saline (PBS) pH 7.4, between ZT 12 and ZT 12:30 in the fed state. After fixation, brains were removed and left in the same fixative overnight at 4 °C. Then, brains were cut into 50-μm coronal sections using a vibratome (VT1200S; Leica Co, Wetzlar, Germany) and stored at −30 °C using cryoprotective solution until immunohistochemistry.

Immunohistochemistry. Free-floating sections were blocked with Triton X-100 (0.3%; 30 min) and bovine serum albumin solution (5%; 1 h) at room temperature. They were then incubated in diluted blocking buffer (Blocking one, NACALAI TESQUE, Japan) and 0.2% sodium azide for 5 days at 4 °C with the following antibodies: rabbit anti-cFos (226 003, Synaptic Systems, Goettingen, Germany, RRID: AB_2231974), and mouse anti-drd1 (sc-33660, Santa Cruz Biotechnology, Dallas, TX, USA, RRID: AB_668813). The sections were then incubated with Tween-20 (0.05%); 40 min) followed by Alexa Fluor 488-conjugated anti-rabbit IgG secondary antibody (Invitrogen; RRID: AB_221544), Alexa Fluor 594 conjugated anti-mouse IgG secondary antibody (Invitrogen; RRID: AB_2650601), and DAPI (525; DOJINDO, Kumamoto, Japan) for 2 h at room temperature. After washing in Tween-20 (0.05%), sections were placed on slides, air dried, and Vectashield (Vector Labs, Peterborough, UK) used to fix coverslips in place. All fluorescently stained sections were examined with either a confocal laser microscope (TIEA1R; NIKON INSTEC, Tokyo, Japan) or a fluorescence microscope (BZ-9000; Keyence, Osaka, Japan; RRID:SCR_015486), and viewed using NIS-Elements software (NIKON INSTEC; RRID:SCR_014329). Cells labeled for cFos colocalization, with or without drd1, were counted bilaterally in a blinded fashion. cFos was merged with nuclear marker (DAPI), while drd1 was expressed in the cytoplasm. For analysis, samples from 4–10 mice from each group were used for staining and the mean values from two or three serial sections from each mouse were calculated. The sections included the CPu and NAc, which were located 1.10–1.42 mm from the bregma based on coordinates in a mouse brain atlas. The anatomical boundaries of each brain region were also identified using the mouse brain atlas37.

Statistical analysis. The statistical significance of differences between groups was analyzed by either unpaired t-test, two-way factorial analysis of variance (ANOVA) or two-way ANOVA assessed by repeated measures followed by Sidak’s multiple comparison by using SPSS Statistics 26 (IBM, Endicott, NY, USA; RRID:SCR_002865). Results are expressed as mean ± standard error of the mean (SEM), and differences were considered significant at p < 0.05.

Data availability The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.
3. Corwin, R. L. & Buda-Levin, A. Behavioral models of binge-type eating.
2. Perello, M., Valdivia, S., García Romero, G. & Raingo, J. Considerations about rodent models of binge eating episodes. Front. Psychol. 5, 372. https://doi.org/10.3389/fpsyg.2014.00372 (2014).

5. Kenny, P. J. Common cellular and molecular mechanisms in obesity and drug addiction.
8. Lardeux, S., Kim, J. J. & Nicola, S. M. Intermittent access to sweet high-fat liquid induces increased palatability and motivation to consume in a rat model of binge consumption. Physiol. Behav. 114–115, 21–31. https://doi.org/10.1016/j.physbeh.2013.03.005 (2013).

11. Liang, N. C., Hajnal, A. & Norgren, R. Sham feeding corn oil increases accumbens dopamine in the rat. Physiol. Behav. 84, 835–867. https://doi.org/10.1016/j.physbeh.2003.03.004 (2003).

16. Arima, H. & Oiso, Y. Positive effect of baclofen on body weight reduction in obese subjects: a pilot study. Intern. Med. 49, 2043–2047. https://doi.org/10.2169/internalmedicine.49.3918 (2010).

1. Kessler, R. M., Hutson, P. H., Herman, B. K. & Potenza, M. N. The neurobiological basis of binge-eating disorder. Neurosci. Biobehav. Rev. 63, 223–238. https://doi.org/10.1016/j.neubiorev.2016.01.013 (2016).

2. Perello, M., Valdivia, S., García Romero, G. & Raingo, J. Considerations about rodent models of binge eating episodes. Front. Psychol. 5, 372. https://doi.org/10.3389/fpsyg.2014.00372 (2014).

3. Corwin, R. L. & Buda-Levin, A. Behavioral models of binge-type eating. Physiol. Behav. 82, 123–130. https://doi.org/10.1016/j.physbeh.2004.04.036 (2004).

4. Waterston, M. J. & Horvath, T. L. Neuronal regulation of energy homeostasis beyond the hypothalamus and feeding. Cell Metab. 22, 962–970. https://doi.org/10.1016/j.cmet.2015.09.026 (2015).

7. Naef, L., Pitman, K. A. & Borgland, S. L. Mesolimbic dopamine and its neuromodulators in obesity and binge eating.
35. Tsunekawa, T. et al. Deficiency of PTP1B attenuates hypothalamic inflammation via activation of the JAK2-STAT3 PATHWAY IN MICROGLIA. *EBioMedicine* **16**, 172–183. https://doi.org/10.1016/j.ebiom.2017.01.007 (2017).
36. Paxinos, G. & Franklin, K. B. J. *The Mouse Brain in Stereotaxic Coordinates* 2nd edn. (Academic Press, 2001).

**Acknowledgements**
We thank Michiko Yamada for helpful technical assistance. This work was supported by a Grant-in-Aid for Scientific Research (C) from the Japanese Society for Promotion of Science (15K09426), a Junior Scientist Development Grant supported by Novo Nordisk Pharma Ltd. from the Japan Diabetes Society, a grant from the Suzuken Memorial Foundation and Swiss National Science Foundation grant 31003A-152970.

**Author contributions**
R.S., T.T., R.B., B.B., and H.A. designed the study and wrote the manuscript. R.S. and T.T. performed the experiments and analyzed the data with technical help and advice from T.H., H.Y., K.T., A.M., M.S., Y.I., H.T., and R.B. The data were interpreted by T.M., T.K., T.O., D.H., S.I., and H.S.

**Competing interests**
The authors declare no competing interests.

**Additional information**
*Supplementary Information* The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98590-9.

*Correspondence* and requests for materials should be addressed to T.T. or H.A.

*Reprints and permissions information* is available at www.nature.com/reprints.

*Publisher’s note* Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*Open Access* This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021